vs

Side-by-side financial comparison of Ibotta, Inc. (IBTA) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $88.5M, roughly 1.4× Ibotta, Inc.). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -10.0%). Ibotta, Inc. produced more free cash flow last quarter ($20.3M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs 3.7%).

Ibotta, Inc. is an American mobile technology company headquartered in Denver, Colorado. Founded in 2011, the company offers cash back rewards on various purchases through its Ibotta Performance Network and direct to consumer app. Ibotta partners with CPG brands and network publishers to provide these rewards. As of 2024, the company operates solely in the United States. The company's rewards-as-a-service offering, the Ibotta Performance Network, went live in 2022.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

IBTA vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
1.4× larger
ZLAB
$127.1M
$88.5M
IBTA
Growing faster (revenue YoY)
ZLAB
ZLAB
+27.1% gap
ZLAB
17.1%
-10.0%
IBTA
More free cash flow
IBTA
IBTA
$47.0M more FCF
IBTA
$20.3M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
3.7%
IBTA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBTA
IBTA
ZLAB
ZLAB
Revenue
$88.5M
$127.1M
Net Profit
Gross Margin
78.7%
51.0%
Operating Margin
-1.9%
-54.6%
Net Margin
Revenue YoY
-10.0%
17.1%
Net Profit YoY
EPS (diluted)
$-0.03
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBTA
IBTA
ZLAB
ZLAB
Q4 25
$88.5M
$127.1M
Q3 25
$83.3M
$115.4M
Q2 25
$86.0M
$109.1M
Q1 25
$84.6M
$105.7M
Q4 24
$98.4M
$108.5M
Q3 24
$98.6M
$101.8M
Q2 24
$87.9M
$100.1M
Q1 24
$82.3M
$87.1M
Net Profit
IBTA
IBTA
ZLAB
ZLAB
Q4 25
Q3 25
$1.5M
$-36.0M
Q2 25
$2.5M
$-40.7M
Q1 25
$555.0K
$-48.4M
Q4 24
Q3 24
$17.2M
$-41.7M
Q2 24
$-34.0M
$-80.3M
Q1 24
$9.3M
$-53.5M
Gross Margin
IBTA
IBTA
ZLAB
ZLAB
Q4 25
78.7%
51.0%
Q3 25
79.4%
59.5%
Q2 25
79.2%
60.6%
Q1 25
79.8%
63.6%
Q4 24
84.6%
61.5%
Q3 24
87.7%
64.1%
Q2 24
86.0%
64.9%
Q1 24
87.2%
61.4%
Operating Margin
IBTA
IBTA
ZLAB
ZLAB
Q4 25
-1.9%
-54.6%
Q3 25
2.8%
-42.3%
Q2 25
1.4%
-50.3%
Q1 25
-3.3%
-53.3%
Q4 24
13.2%
-62.6%
Q3 24
21.0%
-66.6%
Q2 24
-24.6%
-76.0%
Q1 24
19.3%
-80.7%
Net Margin
IBTA
IBTA
ZLAB
ZLAB
Q4 25
Q3 25
1.8%
-31.2%
Q2 25
2.9%
-37.3%
Q1 25
0.7%
-45.8%
Q4 24
Q3 24
17.5%
-40.9%
Q2 24
-38.6%
-80.2%
Q1 24
11.3%
-61.4%
EPS (diluted)
IBTA
IBTA
ZLAB
ZLAB
Q4 25
$-0.03
$-0.05
Q3 25
$0.05
$-0.03
Q2 25
$0.08
$-0.04
Q1 25
$0.02
$-0.04
Q4 24
$3.04
$-0.09
Q3 24
$0.51
$-0.04
Q2 24
$-1.32
$-0.08
Q1 24
$0.33
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBTA
IBTA
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$186.6M
$689.6M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$287.7M
$715.5M
Total Assets
$525.9M
$1.2B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBTA
IBTA
ZLAB
ZLAB
Q4 25
$186.6M
$689.6M
Q3 25
$223.3M
$717.2M
Q2 25
$250.5M
$732.2M
Q1 25
$297.1M
$757.3M
Q4 24
$349.3M
$779.7M
Q3 24
$341.3M
$616.1M
Q2 24
$317.9M
$630.0M
Q1 24
$79.5M
$650.8M
Total Debt
IBTA
IBTA
ZLAB
ZLAB
Q4 25
$0
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$65.3M
Stockholders' Equity
IBTA
IBTA
ZLAB
ZLAB
Q4 25
$287.7M
$715.5M
Q3 25
$329.6M
$759.9M
Q2 25
$354.1M
$791.7M
Q1 25
$401.3M
$810.8M
Q4 24
$457.3M
$840.9M
Q3 24
$378.0M
$667.7M
Q2 24
$359.7M
$704.2M
Q1 24
$44.1M
$762.2M
Total Assets
IBTA
IBTA
ZLAB
ZLAB
Q4 25
$525.9M
$1.2B
Q3 25
$569.4M
$1.2B
Q2 25
$600.8M
$1.2B
Q1 25
$639.3M
$1.2B
Q4 24
$678.4M
$1.2B
Q3 24
$598.3M
$985.3M
Q2 24
$556.0M
$987.4M
Q1 24
$322.1M
$988.4M
Debt / Equity
IBTA
IBTA
ZLAB
ZLAB
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBTA
IBTA
ZLAB
ZLAB
Operating Cash FlowLast quarter
$27.8M
$-26.0M
Free Cash FlowOCF − Capex
$20.3M
$-26.7M
FCF MarginFCF / Revenue
22.9%
-21.0%
Capex IntensityCapex / Revenue
8.5%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$75.0M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBTA
IBTA
ZLAB
ZLAB
Q4 25
$27.8M
$-26.0M
Q3 25
$21.8M
$-32.0M
Q2 25
$25.9M
$-31.0M
Q1 25
$19.9M
$-61.7M
Q4 24
$22.0M
$-55.8M
Q3 24
$39.5M
$-26.8M
Q2 24
$35.0M
$-42.2M
Q1 24
$19.4M
$-90.1M
Free Cash Flow
IBTA
IBTA
ZLAB
ZLAB
Q4 25
$20.3M
$-26.7M
Q3 25
$14.5M
$-35.0M
Q2 25
$22.2M
$-33.9M
Q1 25
$18.0M
$-63.2M
Q4 24
$21.8M
$-58.4M
Q3 24
$39.2M
$-28.2M
Q2 24
$34.8M
$-42.9M
Q1 24
$19.2M
$-91.1M
FCF Margin
IBTA
IBTA
ZLAB
ZLAB
Q4 25
22.9%
-21.0%
Q3 25
17.4%
-30.4%
Q2 25
25.8%
-31.1%
Q1 25
21.2%
-59.9%
Q4 24
22.1%
-53.8%
Q3 24
39.8%
-27.7%
Q2 24
39.6%
-42.9%
Q1 24
23.3%
-104.5%
Capex Intensity
IBTA
IBTA
ZLAB
ZLAB
Q4 25
8.5%
0.5%
Q3 25
8.7%
2.6%
Q2 25
4.2%
2.6%
Q1 25
2.2%
1.5%
Q4 24
0.2%
2.4%
Q3 24
0.3%
1.3%
Q2 24
0.2%
0.7%
Q1 24
0.2%
1.1%
Cash Conversion
IBTA
IBTA
ZLAB
ZLAB
Q4 25
Q3 25
14.19×
Q2 25
10.38×
Q1 25
35.78×
Q4 24
Q3 24
2.29×
Q2 24
Q1 24
2.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBTA
IBTA

Redemption Revenue$78.5M89%
Ad Other Revenue$10.0M11%
Breakage$2.1M2%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons